Every Form 4 that Evoke Pharma, Inc. (EVOK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EVOK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVOK filings page.
Evoke Pharma Inc. director Greg Pyszczymuka filed a report of insider transactions tied to the company’s merger with QOL Medical, LLC. QOL-EOS Merger Sub, Inc. merged into Evoke Pharma effective December 17, 2025, leaving Evoke as a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each outstanding stock option to buy Evoke common stock fully vested, was canceled, and was converted into a right to receive cash. The cash amount for each option is based on the number of underlying shares multiplied by $11.00 minus the option’s exercise price, as specified in the merger agreement.
Evoke Pharma Inc. director Benjamin C. Smeal reported the cash-out of his stock options in connection with the company’s merger with QOL Medical, LLC. A QOL-owned merger subsidiary combined with Evoke Pharma on December 17, 2025, leaving Evoke as a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each option to buy Evoke common stock fully vested, was canceled, and converted into a right to receive cash. The cash amount for each option was based on the number of underlying shares multiplied by $11.00 per share minus the option’s exercise price, paid without interest. The reported transactions include stock options to purchase 5,833 shares at an exercise price of $5.51 and 1,125 shares at an exercise price of $3.453, both of which were disposed of in this process.
Evoke Pharma Inc. executive Marilyn R. Carlson reported equity transactions tied to the company’s sale to QOL Medical, LLC. On December 16, 2025, purchasers completed a tender offer to acquire all outstanding Evoke Pharma common shares for $11.00 in cash per share, followed by a merger on December 17, 2025 that made Evoke a wholly owned subsidiary of QOL Medical.
Carlson, the company’s Chief Medical Officer, reported the disposition of 360 shares of common stock and the cancellation of stock options covering 17,291 and 11,000 shares. Under the merger agreement, each outstanding stock option became fully vested and was converted into the right to receive a cash payment equal to the number of underlying shares multiplied by the difference between the $11.00 offer price and the option’s exercise price.
Evoke Pharma director Cam L. Garner reported transactions tied to the company’s sale to QOL Medical. On December 16, 2025, Purchasers completed a tender offer to acquire all Evoke Pharma common shares for $11.00 per share in cash. Garner’s indirectly held 2,330 shares of common stock through Garner Investments, L.L.C., which were disposed of in connection with the deal.
After the tender offer, a merger became effective on December 17, 2025, making Evoke Pharma a wholly owned subsidiary of QOL Medical. At the merger time, each outstanding stock option automatically vested, was canceled, and converted into a cash right equal to the number of option shares multiplied by the difference between the $11.00 offer price and the option’s exercise price. Following these transactions, the reported stock options show a remaining balance of zero.
Evoke Pharma Inc. director Malcolm R. Hill reported the cash-out of his remaining equity as the company was acquired. On December 16, 2025, all issued and outstanding shares of Evoke common stock were tendered to QOL Medical, LLC and its subsidiary for $11.00 per share in cash under a Merger Agreement dated November 3, 2025. Hill disposed of 133 common shares in this transaction, leaving him with no directly held common stock afterward.
Following completion of the tender offer, the merger closed on December 17, 2025, and Evoke became a wholly owned subsidiary of QOL Medical. Immediately before the merger became effective, each outstanding stock option, including Hill’s options with exercise prices of $5.41, $4.45, and $3.453, fully vested, was canceled, and was converted into a right to receive cash equal to the spread between the $11.00 offer price and the option’s exercise price, multiplied by the number of shares subject to the option.
Evoke Pharma Inc. reported insider share and option dispositions by its Chief Financial Officer, reflecting the completion of a cash acquisition. On December 16, 2025, the CFO disposed of 11,815 shares of common stock in connection with a tender offer in which purchasers agreed to acquire all issued and outstanding Evoke common shares for $11.00 per share in cash.
After the tender offer, a merger closed on December 17, 2025, with Evoke becoming a wholly owned subsidiary of QOL Medical, LLC. Immediately before the merger became effective, each outstanding stock option, including options over 17,291 shares at $5.27 and 13,000 shares at $4.45 per share, fully vested and was canceled and converted into a cash right based on the $11.00 offer price minus the applicable exercise price.
Evoke Pharma Inc director Kenneth J. Widder reported the cash-out and cancellation of his stock options in connection with the company’s acquisition. Under a merger agreement among Evoke, QOL Medical, LLC and a QOL subsidiary, that subsidiary merged into Evoke on December 17, 2025, making Evoke a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each Evoke stock option became fully vested and was automatically canceled. Each option was converted into the right to receive cash equal to the number of shares underlying the option multiplied by $11.00 minus the option’s per share exercise price. After these transactions, the reported derivative positions for this insider were reduced to zero.
Evoke Pharma Inc. has been acquired by QOL Medical, LLC through a tender offer and merger. Purchasers completed a tender offer to buy all outstanding Evoke common shares for $11.00 in cash per share, followed by a merger that made Evoke a wholly owned subsidiary of QOL Medical. In this context, director Todd C. Brady reported disposing of 27 shares of common stock on December 16, 2025, leaving him with no directly owned shares after the transaction.
Immediately before the merger became effective on December 17, 2025, all outstanding stock options accelerated, became fully vested, and were canceled in exchange for cash. Each option holder became entitled to a cash payment equal to the number of shares underlying the option multiplied by the difference between the $11.00 offer price and the option’s exercise price.
Evoke Pharma Inc. director Vickie S. Reed reported the cancellation of her stock options in connection with the company’s merger with QOL Medical, LLC. Under a November 3, 2025 merger agreement, QOL-EOS Merger Sub, Inc. merged into Evoke Pharma on December 17, 2025, making Evoke a wholly owned subsidiary of QOL Medical.
Immediately before the merger became effective, each option to buy Evoke common stock became fully vested, was canceled, and converted into a cash right. The cash amount for each option equals the number of underlying shares multiplied by $11.00 per share minus the option’s per-share exercise price, paid in cash without interest. This Form 4 records those option cancellations and cash-out terms for the reporting director.
Evoke Pharma Inc.'s Chief Executive Officer and director reported stock and option transactions tied to the company’s sale. On December 16, 2025, a tender offer by QOL Medical, LLC and its subsidiary to acquire all Evoke common shares was completed at $11.00 per share in cash. The filing shows a disposition of 15,509 shares of common stock.
Following the tender offer, on December 17, 2025, the merger closed and Evoke became a wholly owned subsidiary of QOL Medical. At the merger’s effective time, all outstanding Evoke stock options, including options for 64,840 shares at an exercise price of $5.27 and 70,000 shares at an exercise price of $4.45, fully vested, were canceled, and converted into a cash right equal to the spread between the $11.00 offer price and the respective exercise prices, multiplied by the number of underlying shares.
Evoke Pharma (EVOK) insider transaction: Roger Klein reported open‑market sales on 11/06/2025, including 5,000 shares at a weighted average price of $10.657 and 4,000 shares at $10.65.
After these trades, 29,000 shares were beneficially owned by his Roth IRA and 125,000 shares by the Krieger Charitable Trust, for which he is sole trustee. He disclaims beneficial ownership except to the extent of his pecuniary interest.